Back to top

vaccines: Archive

Zacks Equity Research

Moderna (MRNA) Beats on Q4 Earnings & Sales, Reiterates View

Moderna (MRNA) beats expectations for earnings and sales. Management reiterates guidance to record around $4 billion from product sales in 2024.

MRKPositive Net Change MRNAPositive Net Change ACETPositive Net Change PBYINegative Net Change

Zacks Equity Research

Moderna (MRNA) Gears Up for Q4 Earnings: Will It Top Estimates?

Investors' focus will likely be on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates, when it reports fourth-quarter earnings.

MRKPositive Net Change MRNAPositive Net Change ARQTPositive Net Change CGEMNegative Net Change

Zacks Equity Research

GSK Lags Q4 Earnings, Tops Sales, Issues Upbeat '24 Guidance

GSK's revenues benefit from strong growth across all segments, especially the Shingles and RSV vaccines. The company also issues fresh 2024 guidance for all its segments.

GSKPositive Net Change AVXLPositive Net Change VIRNegative Net Change

Zacks Equity Research

GSK Gears Up for Q4 Earnings: Will It Surpass Estimates?

We expect GSK's specialty products like Arexvy, Cabenuva, Dovato, Bexsero, Trelegy Ellipta and Shingrix to drive fourth-quarter sales performance.

AZNNegative Net Change GSKPositive Net Change BMRNPositive Net Change MRKPositive Net Change

Zacks Equity Research

Can Moderna's (MRNA) Launches Reduce COVID Sales Dependency?

With COVID-19 vaccine sales declining, Moderna (MRNA) is accelerating the development of its non-COVID pipeline. It is gearing up for potential product launches over the next five years.

PFENegative Net Change MRKPositive Net Change MRNAPositive Net Change